Neupogen 30 MU (0.3 mg/ml) solution for injection *
Pharmacy Only: Prescription

  • Company:

    Amgen Ireland Ltd
  • Status:

    Updated
  • Legal Category:

    Product subject to medical prescription which may be renewed (B)
  • Active Ingredient(s):

    *Additional information is available within the SPC or upon request to the company

Updated on 23 September 2022

File name

632d86323e0c1.pdf

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 23 September 2022

File name

632d856a952b4.pdf

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text
  • Other

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 23 March 2022

File name

uk-ie_neupogen_approved_leaflet_vial_30_v149_1648057720.pdf

Reasons for updating

  • Change to section 6 - date of revision
  • Change to MA holder contact details

Free text change information supplied by the pharmaceutical company

Section 6 Contents of the pack and other information

 Correction to UK MAH address.

Date of revision of the text 

 December 2021

Updated on 15 April 2021

File name

ie_neupogen_approved_spc_vial_30_v144_1618481119.pdf

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 22 May 2019

File name

uk-ie_neupogen_approved_leaflet_vial_30_v137_1558528259.pdf

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 22 May 2019

File name

ie_neupogen_approved_spc_vial_30_v137_1558528230.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.4 Special Warnings and Precautions for use

Patients with rare hereditary problems of fructose intolerance should not take this medicine. Patients with hereditary fructose intolerance (HFI) must not be given this medicine unless strictly necessary.

 

Babies and young children (below 2 years of age) may not yet be diagnosed with hereditary fructose intolerance (HFI). Medicines (containing sorbitol/fructose) given intravenously may be life-threatening and should be contraindicated in this population unless there is an overwhelming clinical need and no alternatives are available.

A detailed history with regard to HFI symptoms has to be taken of each patient prior to being given this medicinal product.

Neupogen contains less than 1 mmol (23 mg) sodium per 0.6 mg/ml, i.e that . is to say essentially‘sodium free’.

Section 4.6 Fertility, pregnancy and lactation

Removal of the following in both the pregnancy and breast-feeding sub headings:

Women who become pregnant during Neupogen treatment are encouraged to enrol in Amgen’s Pregnancy Surveillance Programme. Contact details are provided at the end of the Package Leaflet.

 

Section 10 Date of revision of the text

March 2019

Updated on 06 February 2019

File name

ie_neupogen_approved_spc_vial_30_r04_1549455664.pdf

Reasons for updating

  • Change to section 9 - Date of first authorisation/renewal of the authorisation
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

The following is the changes to the SmPC:

- Section 9 Date of First Authorisation/Renewal of the Authorisation - Date of latest renewal: 21 December 2018

- Section 10 Date of revision of the text - 21 December 2018

Updated on 14 August 2018

File name

uk-ie_neupogen_approved_leaflet_vial_30_v136_1534255361.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 14 August 2018

File name

ie_neupogen_approved_spc_vial_30_v136_1534255251.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

  • In section 4.4 special warnings and precautions for use - a new section for aortitis has been added
  • In section 4.8 undesirable effects - addition of aortitis as a rare adverse reaction (vascular disorder)
  • In section 10 date of revision - the date of revision has been amended to 09th August 2018

File name

PIL_15746_13.pdf

Updated on 15 March 2018

File name

PIL_15746_13.pdf

Reasons for updating

  • New PIL for new product

Updated on 15 March 2018

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 15 March 2018

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.4 Special warnings and precautions for use

Addition of subheadings for clarity; addition of heading for thrombocytopenia

Section 4.7 Effects on ability to drive and use machines

Reworded to include minor influence from dizziness

 

Section 4.8 Undesirable effects

ADR tables amalgamated for all indications.

Revision to reflect updated frequencies

New common event of dizziness

Section 10 Date of revision of the text

March 2018

Updated on 15 March 2018

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 24 April 2017

Reasons for updating

  • Change to section 6 - manufacturer

Updated on 19 October 2015

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.4 - Addition of new section entitled "Glomerulonephritis"
Section 4.8 - Addition of glomerulonephitis to adverse reaction tables, change in frequency of "pain" in cancer patients (uncommon to very common)

Updated on 19 October 2015

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision

Updated on 16 June 2015

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Correction to date of revision

Updated on 28 January 2015

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision

Updated on 27 January 2015

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.4 - Special precautions for storage
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.4 - Addition of text on hypersensitivity/immunogenicity; addition of sickle cell trait to section on sickle cell disease
4.8 - Addition of sickle cell crisis as an uncommon event to tables for PBPC mobilisation in normal donors, SCN patients and HIV patients
6.4 - Addition of instruction to keep in container to protect from light

Updated on 19 November 2014

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Editorial revision to posology information for clarity and consistency across indications

Updated on 03 October 2014

Reasons for updating

  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Update to information on pregnancy and breast feeding based on new preclinical data

Updated on 03 October 2014

Reasons for updating

  • Change to information about pregnancy or lactation
  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 04 February 2014

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.2       Posology and method of administration

In patients treated with myeloablative therapy followed by bone marrow transplantation

 

Revision of text to now state that “The first dose of filgrastim should  be administered  at least 24 hours after cytotoxic chemotherapy and  at least 24 hours  after bone marrow infusion.”

 

4.4       Special warnings and precautions for use

 

Special precautions in cancer patients

·         Addition of information regarding splenomegaly and splenic rupture

 

Special precautions in normal donors undergoing PBPC mobilisation

·         Addition of the following information “Thrombocytopenia has been reported very commonly in patients receiving Neupogen. Platelet counts should therefore be monitored closely.”

 

Special precautions in SCN patients

·  Addition of the following information “Thrombocytopenia has been reported commonly in patients receiving Neupogen.”

 

·         Addition of information regarding splenomegaly and splenic rupture

 

Special precautions in patients with HIV infection

·         Addition of information regarding splenomegaly and splenic rupture

 

4.8          Undesirable effects

 

Cancer patients

·         Addition of splenic rupture as uncommon (≥ 1/1000 to < 1/100) adverse reaction

 

PBPC mobilisation in normal donors

·         Addition of splenic rupture as uncommon (≥ 1/1000 to < 1/100) adverse reaction

 

SCN patients

·         Addition of splenic rupture as a common (≥ 1/100 to < 1/10) adverse reaction

 

Additional information regarding splenomegaly and splenic rupture has been added under the sub-section “Description of selected adverse reactions” for all indications.

 

Information on where to report adverse reactions has been added

 

10.       DATE OF REVISION OF THE TEXT

Date changed to January 2014

Updated on 04 February 2014

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision
  • Change to dosage and administration

Updated on 30 August 2013

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text
  • Change to section 4.4 - Special warnings and precautions for use

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.4 Special warnings and precautions for use

The symptoms of capillary leak are described. Advice is also provided on monitoring and giving patients treatment.

 

Section 4.8 Undesirable effects

Capillary leak syndrome added as a post-marketing potentially life-threatening adverse drug reaction in cancer patients

 

Section 10 Date of revision of the text

Changed to 21 Aug 2013

Updated on 30 August 2013

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 19 July 2013

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.4 Special warnings and precautions for use

Special precautions in normal donors undergoing PBPC mobilisation:

·      Text relating to the long term safety follow-up of normal donors has been deleted.

 

·      To align with section 4.8 of the SmPC the frequency of splenic rupture has been changed from very rare to common.

 

·      To align with section 4.8 of the SmPC dyspnoea has been assigned a frequency of common and the frequency of pulmonary events has been changed from very rare to uncommon.

 

Special precautions in SCN patients:

·      To align with section 4.8 of the SmPC haematuria has been assigned a frequency of common.

 

Section 4.8 Undesirable effects

The Undesirable Effects section (section 4.8) of the SmPC has been revised according to the SmPC guideline (September 2009 version) for the following indications:

·      PBPC mobilisation in normal donors

·      SCN patients

·      Patients with HIV

 

Section 10 Date of revision of the text

Date changed to 4 July 2013

Updated on 19 July 2013

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision

Updated on 24 May 2013

Reasons for updating

  • New individual SPC (was previously included in combined SPC)

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Additional changes to the SmPC include:

Section 4.4 Special warnings and precautions for use
Inclusion of information regarding vascular disorders

Section 4.8 Undesirable effects
Focusing on the chemotherapy induced neutropenia indication the Undesirable Effects section of the SmPC has been revised according to the SmPC guideline, September 2009 version and where necessary consequential changes have been made to the Special Warnings and Precautions for Use section of the SmPC.

Addition of a new sub-section

 

Paediatric SCN patients. 

Cases of decreased bone density and osteoporosis have been reported in paediatric patients with severe chronic neutropenia receiving chronic treatment with Neupogen. The frequency is estimated as ‘common’ from clinical trial data.

 

Section 10 DATE OF REVISION OF THE TEXT
Changed 17 April 2013

Minor administrative changes and corrections throughout the SmPC have also been made to ensure compliance with the latest Quality Review of Documents template (QRD template version 8.0).

Updated on 24 May 2013

Reasons for updating

  • New individual PIL (was previously included in a combined PIL)